Top 4 drugs in GLP-1 Market

Published: June 2026

GLP-1 drugs are a transformative class of therapies in metabolic precision medicine, used to treat type 2 diabetes, obesity and related comorbidities affecting millions worldwide. These engineered molecules mimic the incretin hormone GLP-1. That activates GLP 1 receptors with high specificity, enhancing glucose dependent insulin secretion, suppressing glucagon, delayed gastric emptying, and promoting satiety actions that produce potent metabolic effects and systemic benefits, including cardiovascular protection.

Clinically, GLP-1 therapies deliver substantial weight loss (commonly 15-22% or more with agents such as semaglutide and tirzepatide), improved glycemic control, reduced cardio metabolic risk and better patient reported outcomes versus many traditional regimens. They are available as injectables and oral formulations with favorable pharmacokinetics.

It is important to highlight that a robust development pipeline is extending indications into heart failure, chronic kidney disease, MASH, sleep apnea, and other disorders, which when combined with rising global demand, will expand the GLP-1 market, creating lucrative opportunities for differentiated product strategies and accelerate adoption across care settings. As competitors and payors respond, innovation and broader access will further propel the GLP-1 market and shape the next phase of precision metabolic therapeutics within the GLP-1 market landscape.

Roots Analysis has conducted an exhaustive study of the GLP 1 Market featuring the current market landscape and future opportunities for companies engaged in healthcare, over the span of next 9 years.

Top 4 Drugs in GLP-1 Market:

1. Mounjaro™
2. Zepbound®
3. Ozempic®
4. Wegovy®

The figure below highlights the top 4 drugs in GLP-1 Market:

Top 4 GLP-1 Drugs to watch

Interested in exploring all 150+ GLP-1 drugs along with their recent initiatives?

Discover Below the Details on Top 4 Drugs in GLP-1 Market

Let us dive deep into the details of the top 4 drugs in GLP-1 Market. It is essential to note that the selection of GLP-1 drugs can differ substantially according to the defined criteria.

1. MOUNJARO

The section provides information on various parameters, with details on list of developer, type of molecule, active compound, type of GLP-1 agonist drug, type of agonist, route of administration, dose frequency, and target indication.

Developer: Eli Lilly
Type of Molecule: Peptide
Active Compound: Tirzepatide
Type of GLP-1 Agonist Drug: Long-acting GLP-1 Agonist
Type of Agonist: Dual-agonist
Route of Administration: Subcutaneous
Dosing Frequency: Once Weekly
Target Indication: Type 2 Diabetes

Recent Developments
In May 2026, Eli Lilly presented at the American Diabetes Association's 86th Scientific Sessions, held in New Orleans. The company presented its new findings on cardiometabolic portfolio, including Foundayo, Mounjaro and Retatrutide. These findings are likely to speed clinical uptake, bolster Lilly’s competitive position versus GLP-1 and dual-agonist therapies and support broader GLP-1 drugs market expansion through new indications and increased payer interest.

To know more about the recent initiatives of Mounjaro and other GLP-1 drugs, access full report.

2. Zepbound®

Developer: Eli Lilly
Type of Molecule: Peptide
Active Compound: Tirzepatide
Type of GLP-1 Agonist Drug: Long-acting GLP-1 Agonist
Type of Agonist: Dual-agonist
Route of Administration: Subcutaneous
Dosing Frequency: Once Weekly
Target Indication: Obesity

Recent Developments

In May 2026, Eli Lilly announced results from the SURMOUNT-MAINTAIN trial, published in The Lancet, demonstrating that lower-dose Zepbound® (5 mg) effectively helped patients maintain substantial weight loss after transitioning from higher-dose injectable incretin therapy, along with improved tolerability.

To know more about the recent initiatives of Zepbound® and other GLP-1 drugs, access full report.

3. Ozempic®

Developer: Novo Nordisk
Type of Molecule: Small Molecule
Active Compound: Semaglutide
Type of GLP-1 Agonist Drug: Long-acting GLP-1 Agonist
Type of Agonist: Single-agonist
Route of Administration: Subcutaneous
Dosing Frequency: Once Weekly
Target Indication: Type 2 Diabetes

Recent Developments

In May 2026, Novo Nordisk launched Ozempic®(semaglutide) oral tablets nationwide (available in 1.5 mg, 4 mg, and 9 mg), featuring an improved formulation and smaller pill size to help patients and clinicians more easily recognize the T2D treatment options.

To know more about the recent initiatives of Ozempic® and other GLP-1 drugs, access full report.

4. Wegovy®

The section provides information on the various parameters, with details on list of developer, type of molecule, active compound, type of GLP-1 agonist drug, type of agonist, route of administration, dose frequency and target indication.

Developer: Novo Nordisk
Type of Molecule: Small Molecule
Active Compound: Semaglutide
Type of GLP-1 Agonist Drug: Long-acting GLP-1 Agonist
Type of Agonist: Single-agonist
Route of Administration: Subcutaneous
Dosing Frequency: Once Weekly
Target Indication: Obesity

Recent Developments

In June 2026, Novo Nordisk presented at the American Diabetes Association's 86th Scientific Sessions, held in New Orleans. The company highlighted that its Wegovy® pill (oral semaglutide 25 mg) has surpassed 3 million prescriptions since its January launch, with one filled roughly every 5 seconds. This milestone underscores the strong demand for convenient oral GLP-1 options and expansion to previously untreated patients. The achievement is expected to drive higher patient adherence, accelerate clinical adoption, bolster Novo Nordisk’s competitive position, and further expand the GLP-1 drugs market.

To know more about the recent initiatives of Wegovy® and other GLP-1 drugs, access full report.

What About Other GLP-1 Drugs Around the World?

The above article features the GLP-1 drugs selected from a pool of more than 150 GLP-1 drugs that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: